Antitubercular nanocarrier monotherapy: study of in-silico molecular docking and in-vitro efficacy of repurposed antiviral drug

Author:

Balasubramanian Arul,Ibrahim Thasin,Ramalingam Kothai

Abstract

Abstract There has to be a breakthrough in tuberculosis (TB) treatment to address issues with drug resistance, patient noncompliance, and dosage frequency. We produced durable therapeutic nanocarriers (NCs) and tested their efficiency in-vitro in macrophages infected with Mycobacterium tuberculosis. Our goal was to decrease adverse effects linked to systemic drug distribution and improve drug concentration at the target site. There are multiple pathways by which antiviral medications induce renal failure. Several novel drugs have been shown to cause direct renal tubular toxicity through their distinct impacts on kidney epithelial cells. In this present study the in-silico docking studies were performed and the silver nanoparticles of the antiviral drug Entecavir was prepared and characterized by using SEM and HR-TEM studies. The prepared nanoparticles were evaluated for its anti-tubercular activity by in-vitro and the results showed the repurposed antiviral drug showed remarkable anti-tubercular activity. There is mounting evidence that the repurposed antitubercular drug Entecavir is a viable new option for treating tuberculosis.

Publisher

IOP Publishing

Reference20 articles.

1. Tuberculosis;Zumla;N. Engl. J. Med.,2013

2. Tuberculosis;Frieden;Lancet (London, England),2003

3. Nanobead-based interventions for the treatment and prevention of tuberculosis;Griffiths;Nat. Rev. Microbiol.,2010

4. Chronic hepatitis B virus infection: treatment strategies for the next millennium;Malik;Ann. Intern. Med.,2000

5. Silver nanoparticles inhibit hepatitis B virus replication;Lu;Antivir. Ther.,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3